“I believe I put some good bricks down.” I told [my boss], I was going to make monoclonal antibodies. He laughed at me. —Lee Nadler, Dana-Farber Cancer Institute Nadler recalled a moment in the late ...

This means that only one type of antibody will bind to a matching antigen. Scientists discovered that we could make antibodies to bind to antigens on other substances, and not just those on pathogens.

Quality Committee's guidance about the monoclonal antibodies calls for shared decision-making and multidisciplinary collaboration in determining whether to initiate treatment. The AAN document ...

Direct comparative efficacy studies are few, and also may have design issues, which make their interpretation difficult. The most serious safety issues for monoclonal antibodies include the risk ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Last month, a monoclonal antibody produced in the leaves of tobacco plants entered phase I clinical trials in the United Kingdom. The antibody, known as P2G12, recognizes an HIV surface protein and is ...

ADCs are newer drugs that combine monoclonal antibodies with chemotherapy drugs. ADCs significantly differ from conventional chemotherapy drugs in that they make it possible to deliver ...

For example, an antibody that can recognise an antigen on the Salmonella bacterium will not recognise an antigen on the HIV virus. Scientists discovered that we can make antibodies to bind to ...